Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT05083208 Recruiting - Clinical trials for Peripheral T-Cell Lymphoma

PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma

Start date: February 20, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a prospective single-arm, multicenter, phase Ib/II clinical trial of PI3Kδ inhibitor Parsaclisib combined with chidamide for the treatment of relapsed/refractory peripheral T-cell lymphoma.

NCT ID: NCT05081479 Recruiting - Lymphoma Clinical Trials

A Study of N-Acetylcysteine (N-AC)in People Receiving CAR T-cell Therapy for Lymphoma

Start date: December 8, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety of N-AC when given in combination with Yescarta to people with lymphoma. This study will test different doses of N-AC to find the highest dose that causes few or mild side effects in participants.

NCT ID: NCT05080166 Recruiting - Lymphoma Clinical Trials

UPLYFT For Lymphoma Survivors

Start date: February 8, 2022
Phase: N/A
Study type: Interventional

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

NCT ID: NCT05079282 Recruiting - Clinical trials for Relapsed or Refractory T Cell Lymphoma

Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma

Start date: December 10, 2021
Phase: Phase 1
Study type: Interventional

This study will investigate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ONO-4685 in patients with relapsed or refractory T cell Lymphoma

NCT ID: NCT05078840 Recruiting - Clinical trials for Lymphoma, Non-Hodgkin's, Adult

PET Adapted Treatment of Patients With Limited Stage DLBCL and no Risk Factors

Start date: June 1, 2021
Phase:
Study type: Observational [Patient Registry]

Prospective, multicenter, phase IV study, of real-life evidence destined to evaluate the feasibility and efficacy of performing a treatment adapted to PET-CT in patients with stage I and II DLBCL, without poor prognostic factors.

NCT ID: NCT05078593 Completed - Lymphoma Clinical Trials

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

Start date: October 11, 2021
Phase: Phase 1
Study type: Interventional

This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.

NCT ID: NCT05077527 Not yet recruiting - HIV Infection Clinical Trials

Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma

Start date: July 20, 2024
Phase: Phase 1
Study type: Interventional

This phase I trial evaluates the side effects and usefulness of axicabtagene clioleucel (a CAR-T therapy) and find out what effect, if any, it has on treating patients with HIV-associated aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or not responded to treatment (refractory). T cells are infection fighting blood cells that can kill tumor cells. Axicabtagene ciloleucel consists of genetically modified T cells, modified to recognize CD-19, a protein on the surface of cancer cells. These CD-19-specific T cells may help the body's immune system identify and kill CD-19-positive B-cell non-Hodgkin lymphoma cells.

NCT ID: NCT05076097 Recruiting - Clinical trials for Mantle Cell Lymphoma

A Study of OLR in First-line Treatment of Mantle Cell Lymphoma

Start date: September 30, 2021
Phase: Phase 2
Study type: Interventional

This is a single-arm, multicenter, open label phase II clinical study to evaluate the efficacy and safety of OLR in the treatment of initially treated mantle cell lymphoma.

NCT ID: NCT05075655 Recruiting - Lymphoma Clinical Trials

Endobronchial Diagnosis of Lymphoma

EnDol
Start date: April 20, 2021
Phase: N/A
Study type: Interventional

The present study aimed to assess the diagnostic performance of ultrasound-guided endobronchial intra-nodal miniforceps biopsy (EBUS-MFB) in the diagnosis of "de novo" mediastinal lymphoma.

NCT ID: NCT05075603 Recruiting - Clinical trials for Refractory Diffuse Large B-cell Lymphoma

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Start date: August 6, 2021
Phase: Phase 1
Study type: Interventional

This is a multicenter Phase 1b study evaluating the safety, tolerability, and preliminary anti-tumor activity of NT-I7 administration following standard of care CD19 CAR T-cell therapy for eligible subjects with r/r LBCL.